Akebia Therapeutics Inc (NASDAQ:AKBA) Reports A Drop Of 11.94% In 2020...

0
Akebia Therapeutics Inc (NASDAQ:AKBA) posted total revenues of $25.37 million (down 11.94% YoY) in 2020 and $56.7 million (down 18.47%) in Q4 2020. Signs a...

Boon Industries (OTCMKTS:BNOW) Ramps Toward Potential Breakout as DiOx+ Gains Traction

0
The pandemic health crisis has activated investor interest in a number of different market sectors, with chemicals being one of the most...

Popular News

MAKE IT MODERN

LATEST REVIEWS

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Posts Net TIBSOVO® Revenue Of $31.7 Million...

0
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) has announced its Q3 2020 financial results and provided business highlights. Agios posted total revenue of $34.7 million in Q3 In Q3...

MAKE IT MODERN

PERFORMANCE TRAINING

Jaguar Health Inc. (NASDAQ:JAGX) Subsidiary Napo Pharmaceuticals Announces the Filing of New Drug Application

0
Covid-19 has touched everyone across the globe because if you are not infected, you are affected. People and businesses are becoming helpless and distressed...

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Finalizes The Enrollment Of 36 Subjects In Ad-RTS-hIL-12 Phase 2...

0
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has announced that it completed enrolling 36 patients in its phase 2 clinical trial designed to evaluate a drug combo...

Verastem Inc. (NASDAQ:VSTM) Commences Second Phase VS-6766 Study In KRAS Mutant NSCLC Patients

0
Verastem Inc. (NASDAQ:VSTM) has announced the commencement of a second phase registration-directed clinical study of VS-6766 in patients with KRAS mutant non-small cell lung...

Vaxart Inc. (NASDAQ:VXRT) Receives FDA Clearance For Oral COVID-19 Vaccine To Commence Phase 1...

0
Vaxart Inc. (NASDAQ:VXRT) is moving closer to having clinical data for its oral COVID-19 vaccine candidate after it announced that the FDA had cleared...

Atara Biotherapeutics Inc. (NASDAQ:ATRA) Presents Positive ATA188 Study Data Showing Safety and Sustained Disability...

0
Atara Biotherapeutics Inc. (NASDAQ:ATRA) has announced the release of efficacy and safety data of its First Phase  ATA 188 study in progressive forms of...

MAKE IT MODERN

POPULAR

[/tdc_zone]

.td-post-views{ display: none !important; }